McKesson (MCK) Competitors $713.71 +0.92 (+0.13%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCK vs. COR, CAH, HSIC, PDCO, OMI, HLF, NUS, COSM, HWH, and MEDSShould you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), Herbalife (HLF), Nu Skin Enterprises (NUS), Cosmos Health (COSM), HWH International (HWH), and TRxADE HEALTH (MEDS). McKesson vs. Cencora Cardinal Health Henry Schein Patterson Companies Owens & Minor Herbalife Nu Skin Enterprises Cosmos Health HWH International TRxADE HEALTH Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends. Which has better valuation and earnings, COR or MCK? McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCencora$638.56M88.55$1.51B$7.0341.48McKesson$344.58B0.26$3.00B$21.8432.60 Do analysts recommend COR or MCK? Cencora currently has a consensus price target of $290.00, suggesting a potential downside of 0.55%. McKesson has a consensus price target of $681.00, suggesting a potential downside of 4.37%. Given Cencora's higher probable upside, analysts plainly believe Cencora is more favorable than McKesson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cencora 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78McKesson 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.88 Do institutionals & insiders believe in COR or MCK? 97.5% of Cencora shares are held by institutional investors. Comparatively, 85.1% of McKesson shares are held by institutional investors. 10.8% of Cencora shares are held by insiders. Comparatively, 0.1% of McKesson shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to COR or MCK? In the previous week, McKesson had 8 more articles in the media than Cencora. MarketBeat recorded 37 mentions for McKesson and 29 mentions for Cencora. Cencora's average media sentiment score of 1.46 beat McKesson's score of 1.23 indicating that Cencora is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cencora 26 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive McKesson 30 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, COR or MCK? Cencora has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Is COR or MCK more profitable? McKesson has a net margin of 0.82% compared to Cencora's net margin of 0.46%. Cencora's return on equity of 328.62% beat McKesson's return on equity.Company Net Margins Return on Equity Return on Assets Cencora0.46% 328.62% 4.23% McKesson 0.82%-181.26%5.34% Is COR or MCK a better dividend stock? Cencora pays an annual dividend of $2.20 per share and has a dividend yield of 0.8%. McKesson pays an annual dividend of $2.84 per share and has a dividend yield of 0.4%. Cencora pays out 31.3% of its earnings in the form of a dividend. McKesson pays out 13.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has increased its dividend for 15 consecutive years and McKesson has increased its dividend for 17 consecutive years. Does the MarketBeat Community believe in COR or MCK? McKesson received 228 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.22% of users gave McKesson an outperform vote while only 65.21% of users gave Cencora an outperform vote. CompanyUnderperformOutperformCencoraOutperform Votes74865.21% Underperform Votes39934.79% McKessonOutperform Votes97674.22% Underperform Votes33925.78% SummaryMcKesson beats Cencora on 13 of the 22 factors compared between the two stocks. Get McKesson News Delivered to You Automatically Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCK vs. The Competition Export to ExcelMetricMcKessonDrugs, proprietaries, & sundries IndustryMedical SectorNYSE ExchangeMarket Cap$89.29B$23.03B$5.49B$18.91BDividend Yield0.41%1.53%5.11%4.02%P/E Ratio32.6212.8322.5832.86Price / Sales0.269.88397.2527.79Price / Cash18.3812.9538.1817.52Price / Book-33.0033.236.704.47Net Income$3.00B$785.39M$3.23B$1.02B7 Day Performance3.46%3.49%1.26%0.60%1 Month Performance5.60%-2.35%3.75%-2.74%1 Year Performance34.05%-8.35%15.78%4.48% McKesson Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCKMcKesson4.4773 of 5 stars$713.71+0.1%$681.00-4.6%+32.7%$89.43B$344.58B32.6775,000Upcoming EarningsDividend AnnouncementAnalyst ForecastPositive NewsCORCencora4.2434 of 5 stars$286.95+0.4%$284.55-0.8%+22.5%$55.66B$638.56M40.8342,000Upcoming EarningsAnalyst ForecastPositive NewsCAHCardinal Health4.4461 of 5 stars$137.76+0.1%$140.86+2.2%+37.1%$33.29B$222.28B25.7146,500Earnings ReportAnalyst ForecastShort Interest ↑News CoveragePositive NewsHSICHenry Schein3.5418 of 5 stars$65.35+0.3%$81.10+24.1%-6.2%$8.01B$12.67B26.9022,000Upcoming EarningsAnalyst ForecastPDCOPatterson Companies3.4503 of 5 stars$31.33flat$26.57-15.2%N/A$2.77B$6.51B18.327,700Analyst ForecastPositive NewsOMIOwens & Minor4.7128 of 5 stars$6.79-2.4%$12.50+84.2%-71.6%$524.33M$10.70B-10.4422,500Upcoming EarningsShort Interest ↑HLFHerbalife4.5195 of 5 stars$6.87+2.9%$12.00+74.8%-16.4%$695.71M$4.99B2.7610,100Earnings ReportAnalyst DowngradeNews CoverageGap DownNUSNu Skin Enterprises3.8262 of 5 stars$5.78+0.2%$6.88+18.9%-46.2%$288.44M$1.73B-1.9713,400Upcoming EarningsCOSMCosmos Health2.7438 of 5 stars$0.43+2.1%N/A-38.0%$11.98M$54.43M-0.18100Short Interest ↓Positive NewsHWHHWH InternationalN/A$1.15-4.5%N/A-87.7%$7.42M$1.25M0.00N/AShort Interest ↓MEDSTRxADE HEALTHN/A$0.99+4.2%N/A-84.2%$1.39M$7.45M0.0050News Coverage Related Companies and Tools Related Companies COR Competitors CAH Competitors HSIC Competitors PDCO Competitors OMI Competitors HLF Competitors NUS Competitors COSM Competitors HWH Competitors MEDS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MCK) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding McKesson Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share McKesson With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.